8-K: Centene Reaffirms 2024 Earnings Guidance Ahead of Investor Meetings

Centene Corporation reaffirms its full-year 2024 adjusted diluted earnings per share guidance of greater than $6.80 ahead of investor meetings and a conference presentation.

Summary

• Centene Corporation is scheduled to meet with investors on September 17, 2024.
• The company will also present at the Bank of America 2024 Global Healthcare Conference in London on September 18, 2024.
• Centene expects to reaffirm its 2024 full-year adjusted diluted earnings per share (EPS) guidance of greater than $6.80.
• The company uses non-GAAP financial measures to assess its performance and believes these measures help investors understand its core operations.
• Centene acknowledges that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from projections.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The reaffirmation of guidance is positive, but the document also highlights numerous risks and uncertainties, which tempers the overall sentiment.

Positives

• The reaffirmation of the 2024 earnings guidance provides stability and confidence to investors.
• The use of non-GAAP measures allows for a clearer understanding of the company's core performance.

Negatives

• The company is unable to provide a reconciliation of its 2024 adjusted diluted EPS guidance to the most directly comparable GAAP financial measure.
• The document highlights numerous risks and uncertainties that could impact future performance.

Risks

• The company's ability to design and price competitive products is a risk.
• Maintaining or improving CMS Star ratings is crucial for revenue and growth.
• Fluctuations in medical utilization rates can impact financial results.
• Competition for providers and contracts poses a risk.
• The company faces risks related to managing information systems and business transactions.
• Changes in healthcare practices and regulations can affect the business.
• Cyber-attacks and data security incidents are potential threats.
• Legal and regulatory audits and investigations could impact the company.
• The company's investment portfolio is subject to losses.
• Changes in government healthcare programs and regulations pose a risk.
• The company is subject to risks related to economic, social, and political conditions.

Future Outlook

The company expects to reaffirm its 2024 full-year adjusted diluted EPS guidance of greater than $6.80. The guidance is only effective as of the date given and will not be updated or affirmed unless and until the company publicly announces updated or affirmed guidance.

Management Comments

• The Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods.
• The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for planning purposes, by allowing management to focus on period-to-period changes in the Company's core business operations, and in determining employee incentive compensation.

Industry Context

This announcement is typical for a healthcare company providing updates to investors and reaffirming financial guidance. It is common for companies to use non-GAAP measures to highlight core performance and provide a clearer picture of their operations.

Comparison to Industry Standards

• Reaffirming earnings guidance is a common practice among publicly traded healthcare companies, especially before investor conferences.
• The use of non-GAAP measures is widespread in the healthcare industry, with companies like UnitedHealth Group and Humana also using adjusted earnings metrics.
• Centene's focus on adjusted EPS is similar to how other managed care organizations present their financial performance.
• The risks outlined in the document are typical for the healthcare sector, including regulatory changes, competition, and healthcare cost management.

Stakeholder Impact

• Shareholders will be impacted by the reaffirmation of earnings guidance and the company's future performance.
• Employees may be affected by changes in the company's performance and strategic direction.
• Customers may be impacted by changes in healthcare practices and regulations.
• Suppliers and creditors may be affected by the company's financial performance and stability.

Next Steps

• Centene will meet with investors on September 17, 2024.
• Centene will present at the Bank of America 2024 Global Healthcare Conference on September 18, 2024.

Key Dates

Keywords

earnings guidance, non-GAAP, healthcare, investor relations, financial performance, EPS, Centene, regulation, risk